Unfractionated heparin (UFH) is a widely used anticoagulant, particularly in critical care settings, to prevent and treat thromboembolic disorders. Monitoring UFH therapy is crucial to ensure ...

[8] reported that physicians treating patients for pulmonary embolism and deep-vein thrombosis frequently underdosed their patients and were slow to change their heparin therapy. Sixty percent of ...

Heparin-induced thrombocytopenia (HIT) can be a serious complication of unfractionated heparin therapy. There are two types of HIT: Type I HIT: This form is non-immune mediated. Thrombocytopenia ...

A brief overview of the pathophysiology, diagnosis, and treatment of heparin-induced thrombocytopenia (HIT) is discussed. Following any exposure to unfractionated heparin or low-molecular-weight ...

Lifelong therapy using 81 mg to 325 mg daily should ... with STEMI unless a contraindication exists. Unfractionated heparin, low-molecular-weight heparin (enoxaparin or fondaparinux) or ...

The short DNA sequence in purple, [M08s G2]c, is the antidote to prevent severe bleeding in the treatment using the bispecific aptamer Pse08-29 for heparin-induced thrombocytopenia.

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...